International

Jan
2012

OBD presents its breast cancer, prostate and melanoma test results at SingHealth, National Cancer Centre, Singapore (NCCS).

Dec
2011

OBD signs research and development agreement with major diagnostic company in Japan.

Oct
2011

Notification grant for Singapore patent number 200805949-5.

Aug
2011

Notification of grant for New Zealand patent number 571201.

Jul
2011

USA diagnostic Company signs EpiSwitch™ development Agreement for Alzheimer’s and Parkinson’s diseases.

Apr
2011

Development agreement signed with Super Religare Laboratory Ltd., India.

Mar
2011

Notification of grant for European patent number 07712741.3 (EU).

Nov
2010

Oxford BioDynamics signs development agreement with Singapore Health.

Jun
2010

Oxford BioDynamics signs development agreement with major pharmaceutical company in Asia.

Apr
2010

Oxford BioDynamics certified ISO 9001:2008 and 13485:2003 compliant.

Feb
2010

First grant Oxford BioDynamics core patent in South Africa.

Jan
2010

Professor Lucien Peng-Jin Ooi joins the Scientific Advisory Board.

Jan
2010

Mrs Karen Koh becomes Director of Asia.

Dec
2009

OBD executes first Development and End-user licence in Australia for skin cancer with Clinical Laboratories Pty Ltd.

Mar
2009

Formation of Oxford BioDynamics Hepa Pte Limited.